Literature DB >> 3130267

Stimulation of pancreatic secretion in man by a protease inhibitor (camostate).

G Adler1, A Müllenhoff, I Koop, T Bozkurt, B Göke, C Beglinger, R Arnold.   

Abstract

Pancreatic secretion and plasma cholecystokinin (CCK) and secretin levels were measured in 10 healthy volunteers after application of a serine protease inhibitor (camostate) to study the mechanism of feedback regulation. Camostate produced a strong inhibition of trypsin and chymotrypsin activity in duodenal juice for 1 h. This was accompanied by an increase in duodenal aspirate volume and pancreatic enzyme secretion under both basal and secretin-stimulated conditions. Due to inhibition of tryptic activity, survival of lipase activity in duodenal juice was prolonged. In control experiments we ruled out that the volume and the pH of the solution were responsible for stimulation of pancreatic secretion. The protease inhibitor did not alter pancreatic secretion, which was stimulated by a test meal. Plasma levels of CCK and secretin were not changed after duodenal perfusion of camostate. These observations suggest that trypsin and chymotrypsin are involved in feedback regulation of pancreatic secretion in man which is, however, not mediated by CCK or secretin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3130267     DOI: 10.1111/j.1365-2362.1988.tb01173.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

Review 1.  Management of pain in chronic pancreatitis with emphasis on exogenous pancreatic enzymes.

Authors:  Paul M Hobbs; William G Johnson; David Y Graham
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

Review 2.  Perspectives of CCK antagonists in pancreatic research and clinical use. Part I.

Authors:  L C Rovati
Journal:  Int J Pancreatol       Date:  1991-04

3.  No negative feedback regulation between plasma CCK levels and luminal tryptic activities in patients with pancreatic insufficiency.

Authors:  T Nakamura; K Takebe; K Kudoh; M Ishii; K Imamura; H Kikuchi; F Kasai; Y Tandoh; N Yamada; Y Arai
Journal:  Int J Pancreatol       Date:  1995-02

4.  Chronic diversion of bile to the urinary bladder induces pancreatic growth in dogs.

Authors:  M Takahashi; I Sasaki; H Naito; Y Funayama; C Shibata; N Ohtani; S Matsuno
Journal:  J Gastrointest Surg       Date:  2000 Sep-Oct       Impact factor: 3.452

5.  Influence of high-dose pancreatic enzyme treatment on pancreatic function in healthy volunteers.

Authors:  H Friess; J Kleeff; P Malfertheiner; M W Müller; K Homuth; M W Büchler
Journal:  Int J Pancreatol       Date:  1998-04

6.  Gastrin-releasing peptide and CCK after intraduodenal inhibition of proteases in dogs.

Authors:  R Nustede; W E Schmidt; M Jäger; F Stöckmann; H Köhler; U R Fölsch; H J Peiper
Journal:  Int J Pancreatol       Date:  1994-06

7.  Changes in plasma and duodenal cholecystokinin concentrations after pancreatic duct occlusion in rats.

Authors:  K Miyasaka; A Funakoshi; A Jimi; R Nakamura; M Matsumoto; K Kitani
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

8.  Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man.

Authors:  M C Jebbink; J B Jansen; A A Masclee; C B Lamers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

9.  Enzyme replacement therapy for pancreatic insufficiency: present and future.

Authors:  Aaron Fieker; Jessica Philpott; Martine Armand
Journal:  Clin Exp Gastroenterol       Date:  2011-05-04

Review 10.  Candidate drugs against SARS-CoV-2 and COVID-19.

Authors:  Dwight L McKee; Ariane Sternberg; Ulrike Stange; Stefan Laufer; Cord Naujokat
Journal:  Pharmacol Res       Date:  2020-04-29       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.